Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism ALK2 inhibitors(Activin receptor type-1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H28N8O |
InChIKeyXSQKEVGTZSBVBR-UHFFFAOYSA-N |
CAS Registry1628870-27-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 2 | US | 28 Dec 2020 | |
Myelodysplastic Syndromes | Phase 2 | US | 28 Dec 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 10 Jul 2018 | |
Solid tumor | Phase 2 | US | 10 Jul 2018 |
NCT03429218 (AACR2022) Manual | Phase 1 | 24 | (qtpagsipwp) = gfzhskqxmo ofuqpitakx (rcfebjwwvb ) View more | Positive | 15 Jun 2022 |